News
From 23 June, people living with obesity may be eligible to access tirzepatide (Mounjaro®) for weight loss purposes in primary care settings.
This does not mean prescriptions will be provided immediately. It means primary care settings can begin discussions with patients about whether tirzepatide is the right option to improve their health through weight loss.
